Incidence, Risk factors, and Outcomes of Thromboembolism in Patients with Melanoma Receiving Immune Checkpoint Inhibitors, Chemotherapy, or Targeted Therapy: a SEER-Medicare Analysis.
BACKGROUND Little is known about venous thromboembolism (VTE) and arterial thromboembolism (ATE) risk in melanoma patients receiving immune checkpoint inhibitors (ICI), compared to other therapies. OBJECTIVES We assessed incidence, risk factors, and impact on survival of thromboembolism (TE) in patients receiving ICI...